Alena Laschtowitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alena Laschtowitz has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Christoph Schramm
Department of Medicine I and Martin Zeitz Center for Rare Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
3 shared publications - Anna-Maria Liebhoff
Institute of Medical Systems Biology, Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 shared publications Christian Casar
Hamburg Center for Translational Immunology (HCTI), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; I. Department of Medicine, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
2 shared publications- Frank Tacke
Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany
2 shared publications - Johannes Herkel
Department of Medicine I, University Medical Center Hamburg-Eppendorf
2 shared publications - Marcial Sebode
I. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland
2 shared publications
Latest Publications
- Open Access
- 31 March 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (4)
Second-line tacrolimus and mycophenolate mofetil in difficult-to-treat autoimmune hepatitis
Export
- 31 March 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (4)
Open AccessSecond-line tacrolimus and mycophenolate mofetil in difficult-to-treat autoimmune hepatitis
Export
- Top Cited PapersOpen Access
- 19 March 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 71-90
Integrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitis
- 19 March 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 71-90
Top Cited PapersOpen AccessIntegrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitis
- Open Access
- 12 November 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (3) , 101267
Liver transcriptome analysis reveals PSC-attributed gene set associated with fibrosis progression
- 12 November 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (3) , 101267
Open AccessLiver transcriptome analysis reveals PSC-attributed gene set associated with fibrosis progression
- Open Access
- 10 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (6) , 5295
Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression
Chemokines or chemotactic cytokines play a pivotal role in the immune pathogenesis of liver cirrhosis and hepatocellular carcinoma (HCC). Nevertheless, comprehensive cytokine profiling data across different etiologies of liver diseases are lacking. Chemokines might serve as diagnostic and prognostic biomarkers. In our study, we analyzed serum concentrations of 12 inflammation-related chemokines in a cohort of patients (n = 222) with cirrhosis of different etiologies and/or HCC. We compared 97 patients with cirrhosis and treatment-naïve HCC to the chemokine profile of 125 patients with cirrhosis but confirmed absence of HCC. Nine out of twelve chemokines were significantly elevated in sera of cirrhotic patients with HCC compared to HCC-free cirrhosis controls (CCL2, CCL11, CCL17, CCL20, CXCL1, CXCL5, CXCL9, CXCL10, CXCL11). Among those, CXCL5, CXCL9, CXCL10, and CXCL11 were significantly elevated in patients with early HCC according to the Barcelona Clinic Liver Cancer (BCLC) stages 0/A compared to cirrhotic controls without HCC. In patients with HCC, CXCL5 serum levels were associated with tumor progression, and levels of CCL20 and CXCL8 with macrovascular invasion. Importantly, our study identified CXCL5, CXCL9, and CXCL10 as universal HCC markers, independent from underlying etiology of cirrhosis. In conclusion, regardless of the underlying liver disease, patients with cirrhosis share an HCC-specific chemokine profile. CXCL5 may serve as a diagnostic biomarker in cirrhotic patients for early HCC detection as well as for tumor progression.
- 10 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (6) , 5295
Open AccessSerum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression
Chemokines or chemotactic cytokines play a pivotal role in the immune pathogenesis of liver cirrhosis and hepatocellular carcinoma (HCC). Nevertheless, comprehensive cytokine profiling data across different etiologies of liver diseases are lacking. Chemokines might serve as diagnostic and prognostic biomarkers. In our study, we analyzed serum concentrations of 12 inflammation-related chemokines in a cohort of patients (n = 222) with cirrhosis of different etiologies and/or HCC. We compared 97 patients with cirrhosis and treatment-naïve HCC to the chemokine profile of 125 patients with cirrhosis but confirmed absence of HCC. Nine out of twelve chemokines were significantly elevated in sera of cirrhotic patients with HCC compared to HCC-free cirrhosis controls (CCL2, CCL11, CCL17, CCL20, CXCL1, CXCL5, CXCL9, CXCL10, CXCL11). Among those, CXCL5, CXCL9, CXCL10, and CXCL11 were significantly elevated in patients with early HCC according to the Barcelona Clinic Liver Cancer (BCLC) stages 0/A compared to cirrhotic controls without HCC. In patients with HCC, CXCL5 serum levels were associated with tumor progression, and levels of CCL20 and CXCL8 with macrovascular invasion. Importantly, our study identified CXCL5, CXCL9, and CXCL10 as universal HCC markers, independent from underlying etiology of cirrhosis. In conclusion, regardless of the underlying liver disease, patients with cirrhosis share an HCC-specific chemokine profile. CXCL5 may serve as a diagnostic biomarker in cirrhotic patients for early HCC detection as well as for tumor progression.
- Open Access
Pathogen Detection in RNA-Seq Data with Pathonoia
Motivation Recent evidence suggests that bacterial and viral infections may cause or exacerbate many human diseases. One method of choice to detect microbes in tissue is RNA sequencing. While the detection of specific microbes using RNA sequencing offers good sensitivity and specificity, untargeted approaches suffer from very high false positive rates and a lack of sensitivity for lowly abundant organisms. Results We introduce Pathonoia, an algorithm that detects viruses and bacteria in RNA sequencing data with high precision and recall. Pathonoia first applies an established k-mer based method for species identification and then aggregates this evidence over all reads in a sample. In addition, we provide an easy-to-use analysis framework that highlights potential microbe-host cell interactions by correlating the microbial to host gene expression. Pathonoia outperforms competing algorithms in microbial detection specificity, both on in silico and real datasets. Lastly, we present two case studies in human liver and brain in which microbial infection might exacerbate disease. Availability A Python package for Pathonoia sample analysis and a guided analysis Jupyter notebook for bulk RNAseq datasets are available on GitHub https://github.com/kepsi/Pathonoia. Contact aliebho1{at}jhu.edu and s.bonn{at}uke.de
Open AccessPathogen Detection in RNA-Seq Data with Pathonoia
Motivation Recent evidence suggests that bacterial and viral infections may cause or exacerbate many human diseases. One method of choice to detect microbes in tissue is RNA sequencing. While the detection of specific microbes using RNA sequencing offers good sensitivity and specificity, untargeted approaches suffer from very high false positive rates and a lack of sensitivity for lowly abundant organisms. Results We introduce Pathonoia, an algorithm that detects viruses and bacteria in RNA sequencing data with high precision and recall. Pathonoia first applies an established k-mer based method for species identification and then aggregates this evidence over all reads in a sample. In addition, we provide an easy-to-use analysis framework that highlights potential microbe-host cell interactions by correlating the microbial to host gene expression. Pathonoia outperforms competing algorithms in microbial detection specificity, both on in silico and real datasets. Lastly, we present two case studies in human liver and brain in which microbial infection might exacerbate disease. Availability A Python package for Pathonoia sample analysis and a guided analysis Jupyter notebook for bulk RNAseq datasets are available on GitHub https://github.com/kepsi/Pathonoia. Contact aliebho1{at}jhu.edu and s.bonn{at}uke.de
- 1 June 2021
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 64 (6) , 104214
Genetic aspects of adult and pediatric autoimmune hepatitis: A concise review
- 1 June 2021
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 64 (6) , 104214
Genetic aspects of adult and pediatric autoimmune hepatitis: A concise review
- 1 January 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , S632-S633
Redundant Tolerance Mechanisms Prevent Autoimmune Liver Inflammation in Mice
- 1 January 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , S632-S633
Redundant Tolerance Mechanisms Prevent Autoimmune Liver Inflammation in Mice